The role of pharmacogenetics for the benefits sponsor community

The role of pharmacogenetics for the benefits sponsor community

How COVID is forcing the accelerated evolution of health benefits services and the role of pharmacogenetics in helping plan members get the right medications to support recovery from a wide variety of pandemic-related health issues.

Click the image below to read the full article or download the PDF.

Benefits And Pensions Monitor - February 2021 http://www.mirabelsmagazinecentral.com/DigitalEdition/index.html?id=cd2ad482-36b3-49e3-8cb7-de271f4e2ba6&pn=17&pv=d

 

Back to blog

About the author

Veronika Litinski

Veronika Litinski

MSc Medicinal Chemistry, MBA

Veronika is a medicinal chemist by training and first approached the health sector through cancer research at Lawrence Livermore Labs in Berkeley. Subsequently, she worked in capital markets and invested in innovative companies at GATX Capital in San Francisco. Veronika moved to Canada in 2004, where she joined the new MaRS innovation hub in Toronto. During their start-up phase, she was Director of the Venture Group, the ‘engine room’ of MaRS. Later she was Practice Lead for Health, working in one of the most complex and socially important sectors of our economy. Veronika also piloted the launch of Congniciti, a brain health company developed by Baycrest Hospital. She is currently the CEO of GeneYouIn and a leader in bringing precision medicine to health plans and individuals globally.